CR-CP Life Science Fund
VC Fund
Hong Kong, Hong Kong
CR-CP Life Science Fund is a joint venture set up by China Resources Group and Charoen Pokphand Group. This firm invests in life science companies that develop drugs, cell therapies, medical devices, and smart healthcare technology.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries CR-CP Life Science Fund invests in
Stages CR-CP Life Science Fund invests in
Countries CR-CP Life Science Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Da Liu
|
|||
Jason Zhou
|
|||
3 more contacts available
Investment Focus
Industry
- Health Care 10 (67%)
- Biotechnology 9 (60%)
- Medical 5 (33%)
- Therapeutics 3 (20%)
- Medical Device 3 (20%)
Stage
- Series B 7 (47%)
- Series C 4 (27%)
- Series E 2 (13%)
Country
- China 6 (40%)
- Israel 2 (13%)
- United States 2 (13%)
- Belgium 1 (7%)
- Singapore 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Da Liu
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
|
Jason Zhou
CEO & Managing Director
|
CEO & Managing Director | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Novadip Biosciences
|
Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M / Series B / Nov 03, 2022 | |
NuProbe
|
An early stage molecular diagnostics company. | $50M / Series B / Jun 02, 2022 | |
Yueer Gene
|
Yueer is a genetic screening and diagnosis service provider, focusing on applying new genetic technology & international big data algorithms | $50M / Series B / Jun 02, 2022 | |
Mirxes
|
MiRXES offers discover, develop, and deliver accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases, and make them accessible to all. | $87M / Series C / Feb 22, 2022 | |
|
Novadip Biosciences
|
Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $22.2M / Series B / Oct 28, 2021 | |
|
Mirxes
|
MiRXES offers discover, develop, and deliver accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases, and make them accessible to all. | $77M / Series C / Jul 08, 2021 | |
EyeYon
|
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M / Series C / Mar 15, 2021 | |
ReViral
|
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates,enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds. | $44M / Series C / Aug 25, 2020 | |
BELKIN Vision
|
BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $12.3M / Series B / Jul 21, 2020 | |
New Horizon Health
|
New Horizon Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancerscreening into thousands of households so that the public can enjoy convenient and efficient health services . | $30M / Series E / Jul 10, 2020 | |
| See all 15 investments → | |||
Co-Investors
HSG
4 deals together
HSG
3 deals together
Rock Springs Capital
3 deals together
Temasek
3 deals together
Charoen Pokphand Group
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CR-CP Life Science Fund invest in?
CR-CP Life Science Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CR-CP Life Science Fund?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CR-CP Life Science Fund?
The team at CR-CP Life Science Fund includes Da Liu (Managing Director) and Jason Zhou (CEO & Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
